Quantitative Relationship Between Transforming Growth Factor-Alpha and Hepatic Focal Phenotype and Progression in Female Mouse Liver
Open Access
- 1 May 1997
- journal article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 25 (3) , 275-283
- https://doi.org/10.1177/019262339702500305
Abstract
Modulations in the positive hepatocyte growth factor, transforming growth factor-alpha (TGF-α) and its receptor epidermal growth factor receptor (EGFR), occur in rat and human liver tumors. The purpose of this study was to determine if TGF-α and EGFR are altered in basophilic and acidophilic preneoplastic and neoplastic liver lesions generated in DEN-initiated mice exposed to a variety of hepatocarcinogens. Female B6C3F1 mice were initiated with N-nitrosodiethylamine (DEN) and treated with hepatocarcinogenic concentrations of unleaded gasoline vapor (2,000 ppm), methyl tertiary butyl ether vapor (7,814 ppm), phenobarbital (500 ppm, diet), or chlordane (25 ppm, diet). Hepatic foci and tumors were identified and evaluated immunohistochemically with antibodies for TGF-α and EGFR. In all treatment groups, basophilic hepatic foci were negative for TGF-α immunoreactivity (554/564, 98%). In contrast, regardless of treatment, acidophilic hepatic foci were immunoreactive for TGF-α (107/108, 99%). There was no significant difference in mean hepatic labeling index as measured by the incorporation of 5-bromo-2'-deoxyuridine between foci immunoreactive and nonimmunoreactive for TGF-α. The incidence of immunoreactivity for TGF-α increased in hepatocellular tumors that were predominantly of the basophilic phenotype. Of basophilic hepatocellular adenomas, 16/81 (20%) were immunoreactive for TGF-α, while 17/29 (59%) of hepatocellular carcinomas stained positive for TGF-α. A similar increased incidence of EGFR immunoreactivity was found in basophilic hepatocellular adenomas (17/67, 25%) and carcinomas (19/28, 68%) relative to basophilic foci (11/367, 3%), suggesting an autocrine mechanism for the development of mouse liver tumors. The increased incidence of TGF-α immunoreactivity in basophilic liver tumors suggests that TGF-α is a marker of tumor progression in mouse liver. Furthermore, TGF-α modulations were dependent on phenotype rather than treatment, indicating inherent differences in the expression of TGF-α in basophilic and acidophilic hepatic lesions.Keywords
This publication has 35 references indexed in Scilit:
- A Review of the Hepatic Tumors Related to Mixed-Function Oxidase Induction in the MouseToxicologic Pathology, 1996
- The quantitation of altered hepatic foci during multistage hepatocarcinogenesis in the rat: Transforming growth factor α expression as a marker for the stage of progressionCancer Letters, 1995
- Expression of transforming growth factor alpha in human hepatocellular carcinomaLiver International, 1993
- Growth factors in liver development, regeneration and carcinogenesisProgress in Growth Factor Research, 1991
- Growth of normal human hepatocytes in primary culture: Effect of hormones and growth factors on DNA synthesisHepatology, 1991
- Transforming Growth Factors β1 and α in Chronic Liver DiseaseNew England Journal of Medicine, 1991
- A genetic model for colorectal tumorigenesisCell, 1990
- Sequential Changes in Epidermal Growth Factor Receptor/Ligand Function in Cultured Rat Liver Epithelial Cells Transformed Chemically in vitroPathobiology, 1990
- Gamma-glutamyl transpeptidase – its role in hepatocarcinogenesisCarcinogenesis: Integrative Cancer Research, 1985
- Growth factors from murine sarcoma virus-transformed cells.Proceedings of the National Academy of Sciences, 1978